SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for
the third quarter of 2007 on Wednesday, October 17, 2007 at 5:00 p.m.
ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive
Officer, will lead the call. On the same date post market, Amylin will
release financial results for the third quarter of 2007.
The call will be webcast live through Amylin's corporate website and a
recording will be made available following the close of the call. To access
the webcast, please log on to http://www.amylin.com approximately fifteen
minutes prior to the call to register, download and install any necessary
audio software. For those without access to the Internet, the live call may
be accessed by phone by calling (866) 700-6979 (domestic) or (617) 213-8836
(international), passcode 48312438. A replay of the call will also be
available by phone for 24 hours beginning approximately one hour after the
close of the call and can be accessed at (888) 286-8010 (domestic) or (617)
801-6888 (international), passcode 10940869.
About Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed
to improving lives through the discovery, development and commercialization
of innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,800 employees nationwide.
Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Alice Bahner Izzo, Executive Director,
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, ext. 7272
|
